ERBB2 and triple-negative breast carcinoma: As far as hormone receptor (ER and PR) negative and HER2-negative triple-negative breast cancer (TNBC) is concerned, the checkpoint inhibitor atezolizumab has been approved by the FDA for use with the chemotherapeutic agent nab-paclitaxel in patients with advanced TNBC (level of evidence I, A).